Why did Amgen (AMGN) stock move recently?

On 8/5/2026, Amgen moved +4.0% — Amgen's Q2 non-GAAP EPS of $6.29 came in ~12% above consensus on revenue of ~$10.05 billion (up ~9.5% YoY), and it raised full-year revenue guidance to $38.2-39.4 billion on broad portfolio growth led by Repatha and Evenity. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Amgen (AMGN) overvalued or fairly valued?

MarketChacha shows Amgen's valuation in context — a trailing P/E of about 25.4, a forward P/E of about 17.1, a price-to-book of about 19.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Amgen's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.62×) from reported figures — education, not a rating.

What is Amgen's revenue?

Amgen reported revenue of $36.8B for FY2025, with net profit of $7.7B, per official filings.

What is the share price of Amgen (AMGN)?

Amgen last traded at $414.30 (-0.7% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Amgen

AMGN · NASDAQ · Biotech · United States

Snapshot

TickerAMGN

ExchangeNASDAQ

SectorBiotech

IndustryDrug Manufacturers - General

CountryUnited States

Employees31,500

HeadquartersThousand Oaks, United States

Websitewww.amgen.com

Filings tracked16

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Who owns it

Insiders0.2%
Institutions85.5%
Public & other14.3%

3,961 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.13%
Vanguard Capital Management LLC6.48%
State Street Corporation5.65%
Capital World Investors5.42%
Invesco Ltd.2.94%
Morgan Stanley2.93%
Geode Capital Management, LLC2.85%
Vanguard Portfolio Management LLC2.70%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 2.8 points over the period — profitability is trending down.

Cash conversion1.62×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend23.8% → 21.0%

Margin has compressed by about 2.8 points over the period — profitability is trending down.

Return on equity89.1%

Latest ROE of 89.1% — capital is generating a healthy return.

Growth qualityrev 14% · PAT 7%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $10.2B · EPS 5.83

Est. earnings growth +10.2%

Next fiscal year

Rev $39.9B · EPS 24.22

Est. earnings growth +5.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$36.8B

Net margin

21.0%

ROE

89.1%

Revenue CAGR (2y)

+14.2%

Profit CAGR (2y)

+7.1%

EPS (FY2025)

14.23

Net profit (FY2025)

$7.7B

Ask MarketChacha about AMGN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 5, 2026
Amgen's Q2 non-GAAP EPS of $6.29 came in ~12% above consensus on revenue of ~$10.05 billion (up ~9.5% YoY), and it raised full-year revenue guidance to $38.2-39.4 billion on broad portfolio growth led by Repatha and Evenity.
source 1 ↗source 2 ↗· confidence: high
Jul 28, 2026
Amgen shares rose 4.48% as investors positioned ahead of the upcoming Q2 earnings report, reacting positively to a slight upward revision in EPS estimates and looking past the Tavneos regulatory overhang.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$36.8B	$7.7B	14.23	21.0%	89.1%
FY2024	$33.4B	$4.1B	7.56	12.2%	69.6%
FY2023	$28.2B	$6.7B	12.49	23.8%	107.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$10.1B	$2.4B	4.37	23.6%
2026Q1	$8.6B	$1.8B	3.34	21.1%
2025Q3	$9.6B	$3.2B	5.93	33.7%
2025Q2	$9.2B	$1.4B	2.65	15.6%
2025Q1	$8.1B	$1.7B	3.20	21.2%
2024Q3	$8.5B	$2.8B	5.22	33.3%
2024Q2	$8.4B	$746.0M	1.38	8.9%
2024Q1	$7.4B	$-113.0M	-0.21	-1.5%
2023Q3	$6.9B	$1.7B	3.22	25.1%
2023Q2	$7.0B	$1.4B	2.57	19.7%
2023Q1	$6.1B	$2.8B	5.28	46.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC8/4/2026material
8-K filing
SEC7/31/2026material
8-K — Shareholder vote results
SEC5/20/2026material
8-K — Executive/director change
SEC5/19/2026material
10-Q filing
SEC5/1/2026
8-K — Results of operations, Exhibits
SEC4/30/2026material
8-K — Executive/director change, Exhibits
SEC4/22/2026material
8-K — Material agreement, Exhibits
SEC2/19/2026material
10-K filing
SEC2/13/2026
8-K — Results of operations, Exhibits
SEC2/3/2026material
8-K — Termination of agreement, Exhibits
SEC1/30/2026material

2025

10-Q filing
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC11/4/2025material
10-Q filing
SEC8/6/2025
8-K — Results of operations, Exhibits
SEC8/5/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.